In the final analysis, TEMPOL administration at a cumulative dose of 400 μmol/kg before aortic occlusion-induced ischemia and during the early reperfusion phase conferred a protective effect on AKI in terms of renal damage, inflammation, and iNOS production. This evidence concerns the gene NOS2 and acute kidney injury.